Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
ClinicalTrials.gov · NCT07220629 · Registry updated: 2026-10-27
- Condition / research focus
- Obesity
- Sponsor
- NodThera Ltd. (a Rezera company)
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2025-10-02. Completion: 2026-08-21 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- NT-0796 (drug)
- Placebo (drug)
Where the study takes place — 9 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Investigative Site
Mesa, Arizona, United States
Site recruitment: Not reported - Hialeah, Florida, United States